Business Wire

HOGAN-LOVELLS

20.10.2021 12:52:05 CEST | Business Wire | Press release

Share
Hogan Lovells White Paper Calls for Flexibility as the EU Establishes Its First-ever Regulatory Framework Enabling the Launch of Autonomous Vehicles

Global law firm Hogan Lovells has today shared its recommendations on the future of Europe’s regulatory framework for autonomous vehicles (AVs), as the European Commission takes an important first step in submitting a Draft EU ADS Regulation to all 27 Member States ahead of a Public Consultation in November.

The regulatory framework published in late September 2021 will be used to help shape the future of AVs across the EU and will have far reaching implications on the AV industry in Europe for years to come.

The Draft EU ADS Regulation sets out the type-approval rules for AVs with regard to their automated driving system (ADS) to create a harmonised pathway for (SAE/ISO) “Level 4” or “fully automated” vehicles to be deployed on public roads across Member States – with no human driver. It also establishes aggregate safety metrics that will be used to benchmark performance, and ultimately will be used as a measurement for allowing AV testing and deployment.

The Hogan Lovells White Paper “The Road to Autonomous Vehicles” issued today identifies three key recommendations for a legal framework for AVs, which will guide regulatory developments at an EU and national level. They include:

  1. A broad, holistic and forward-looking approach to type-approval across Europe is important. The regulatory framework needs to be as flexible as possible. At a minimum, the existing system for type-approval should be used as a foundation and should not be undone for AVs/ADSs only.

  2. The assumption of regulatory responsibility and proof of safety concept should be considered as the decisive factor for regulations. Expertise is key when it comes to putting AVs onto public roads in the market and needs to be considered when allocating roles and responsibilities for different economic operators.

  3. Avoiding ambiguities (in particular to the existing regulatory framework), inconsistencies and the use of unclear terms and definitions that may lead to interpretation issues and delay the development and commercialisation of AVs.

The Draft EU ADS Regulation is part of a broader maturation in Europe’s AV regulatory environment. Other promising efforts are currently being made by France, Germany and the Netherlands, although Germany appears to be deviating from current existing broad definitions and a flexible approach applied at the EU level. The White Paper highlights that a harmonised approach across Europe providing adequate flexibility will be key for the long-term success of AVs.

Patrick Ayad, Global Leader of Mobility and Transportation at Hogan Lovells, said:

“This is a key piece of research on the future of Europe’s regulatory framework for autonomous vehicles.”

“We have an exciting opportunity to introduce autonomous vehicles in Europe. Current efforts made within Europe are encouraging and align well with the recommendations that we have made in our White Paper today. We need to take a broader and holistic approach to type approval as this will be even more valuable and beneficial for this purpose. Technological innovations, emerging new mobility solutions, as well as commercial and corporate partnerships changing the industry landscape call for a flexible framework – this needs to apply across Europe and individual Member States to work.”

Key highlights from the White Paper include:

- AV technology and the industry landscape are evolving rapidly. Developing an automated driving system (ADS) remains a highly-resource intensive endeavour, requiring extensive technical and specialised expertise.

- The challenge facing regulators is to provide a legal framework to allow for commercial deployment across Europe. This means setting appropriate “type-approval” requirements that meet the dual purposes of ensuring the technology is safe as well as facilitating commercial deployment in a way that will deliver the value the EU Commission has envisaged.

- Steps taken by the French, German and Dutch Governments are encouraging in that they seek to set out the legal basis for the approval of ISO/SAE Level 4 driving automation directly, and not lower-level human driver-assistance systems.

- The shift from conventional vehicles to AVs is a unique and disruptive scenario: it is the first time that not only the vehicle but also the driver (the ADS) are being regulated and type-approved.

- Innovation calls for flexibility. Regulating innovation calls for the same. An open and flexible approach has proven successful for AV testing over many years, building on - rather than replacing - existing regulatory concepts. This same lesson should be applied when it comes to the key question of defining which entity (or group of entities) should be responsible for presenting the AV - that is, the base vehicle and the ADS - to a regulator for type-approval.

- While the European Commission appears to be effectively addressing this issue under its forthcoming ADS Type Approval Implementing Act (which is expected to be in place by July 2022), it seems that the German Government takes a different approach under its current draft for an ordinance implementing the newly adopted changes to road traffic laws enabling regular operation of SAE/ISO Level 4 AVs, which, contrary to existing laws, introduces a new definition for “manufacturer” that refers to the “vehicle manufacturer”.

Hogan Lovells is one of the world's leading law firms in its dedication to an industry sector focused-approach, enabling us to advise our clients in a sector-focused manner, across practice groups, borders and industries.

In 2020, we created a new global Mobility and Transportation sector group, bringing together our already established industry sectors Automotive (and Mobility) and Aerospace and Defence as well as our new industry sector Transport and Logistics, to better represent the rapid changes facing the Mobility and Transportation world.

The full White Paper can be accessed here .

[Ends]

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release

Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release

As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye